Abstract Treatment with therapy targeting BRAF and MEK (BRAF/MEK) has revolutionized
care in melanoma and other cancers; however, therapeutic resistance is common and …

Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer
(PC). Most patients eventually progress to a condition known as castration-resistant prostate …

Urinary tract-associated diseases comprise a complex set of disorders with a variety of
etiologic agents and therapeutic approaches and a huge global burden of disease …

In our effort to find small-molecule treatments of advanced prostate cancers (PCs), a novel
series of indolyl and indolinyl propanamides (series II and III) were discovered as selective …

Scope Cachexia, which is often marked by skeletal muscular atrophy, is one of the leading
causes of death in cancer patients. Astaxanthin, a carotenoid obtained from marine …

The prevailing biomarker employed for prostate cancer (PCa) screening and diagnosis is
the prostate-specific antigen (PSA). Despite excellent sensitivity, PSA lacks specificity …

Kinase inhibitors (KIs) and antiandrogen drugs (AAs) are oral anticancer drugs with narrow
therapeutic index that exhibit high inter-and intra-individual variability. We describe here a …

Background/Aims: Polyphyllin I (PPI), one of the steroidal saponins in Paris polyphylla,
reportedly exhibits antitumor effects. However, the detailed mechanism underlying PPI …

Castration-resistant (androgen-independent) and PTEN-deficient prostate cancer is a
challenge in clinical practice. Sorafenib has been recommended for the treatment of this …

Androgen ablation therapy is the primary therapeutic option for locally advanced and
metastatic castration‐resistant prostate cancer (CRPC). We investigated therapeutic effect of …